Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

4.2K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

61
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Taxonomy bias in metagenome-assembled genome recovery.

Microbial genomics·2026
Same author

DVD-IgG1 antibody-drug conjugates: Expanding the landscape of targeted cancer therapy.

Current opinion in chemical biology·2026
Same author

Discovery of 5‑Chlorotryptophan-Containing Antibiotics through Metabologenomics-Assisted High-Throughput Screening.

JACS Au·2025
Same author

Chemical Tagging of <i>N</i>-Alkylamine-Containing Natural Products and Pharmaceuticals through C(<i>sp</i><sup>3</sup>)-H Functionalization.

Journal of the American Chemical Society·2025
Same author

Logical Exploration of Cinnamoyl-Containing Nonribosomal Peptides via Metabologenomic Targeting and Regulator Overexpression.

Journal of the American Chemical Society·2025
Same author

Second Generation Tiancimycin-Based Antibody-Drug Conjugates Enabled by Highly Efficient Semi-synthetic Approach Specifically Targeting B-Cell Malignancies.

JACS Au·2025

Related Experiment Video

Updated: Mar 13, 2026

Dual Immunofluorescence of &#947;H2AX and 53BP1 in Human Peripheral Lymphocytes
05:34

Dual Immunofluorescence of γH2AX and 53BP1 in Human Peripheral Lymphocytes

Published on: July 14, 2023

2.5K

Zorbamycin has a different DNA sequence selectivity compared with bleomycin and analogues.

Jon K Chen1, Dong Yang1, Ben Shen1

  • 1School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia.

Bioorganic & Medicinal Chemistry
|October 18, 2016
PubMed
Summary

New bleomycin (BLM) analogues were synthesized and tested for DNA sequence specificity. Zorbamycin (ZBM) showed distinct cleavage sites compared to BLM, suggesting potential for novel cancer therapies.

Keywords:
Anti-tumour agentBleomycin analogueDNA cleavageDNA sequence specificityZorbamycin

More Related Videos

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

2.1K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K

Related Experiment Videos

Last Updated: Mar 13, 2026

Dual Immunofluorescence of &#947;H2AX and 53BP1 in Human Peripheral Lymphocytes
05:34

Dual Immunofluorescence of γH2AX and 53BP1 in Human Peripheral Lymphocytes

Published on: July 14, 2023

2.5K
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

2.1K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Medicinal Chemistry

Background:

  • Bleomycin (BLM) is a clinically used chemotherapy agent for various tumors.
  • The BLM drug family includes zorbamycin (ZBM) and other analogues.
  • Developing novel BLM analogues with improved efficacy is crucial for cancer treatment.

Purpose of the Study:

  • To determine the DNA sequence specificity of novel BLM analogues (BLM Z, 6'-deoxy-BLM Z) and zorbamycin (ZBM).
  • To compare the DNA cleavage activity of these compounds with the parent Bleomycin (BLM).
  • To evaluate the potential of these analogues in cancer chemotherapeutics.

Main Methods:

  • Utilized a recently developed high-precision technique for DNA sequence specificity determination.
  • Employed purified plasmid DNA as the substrate for cleavage assays.
  • Compared DNA sequence specificity profiles of BLM, ZBM, BLM Z, and 6'-deoxy-BLM Z.

Main Results:

  • BLM Z and 6'-deoxy-BLM Z exhibited similar DNA sequence specificity to BLM, primarily cleaving at TGTA sequences.
  • Zorbamycin (ZBM) demonstrated a distinct DNA sequence specificity, with predominant cleavage at both TGTA and TGTG sequences.
  • 6'-deoxy-BLM Z showed significantly improved DNA cleavage activity compared to BLM.

Conclusions:

  • Manipulating the BLM biosynthetic machinery is a viable strategy for producing novel BLM analogues.
  • The distinct DNA sequence specificity of ZBM suggests unique therapeutic potential.
  • Novel BLM analogues, like 6'-deoxy-BLM Z, may offer improved cancer chemotherapeutic properties.